Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.45 |
| ▸ | PDE4A | P27815 | 3/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17022872 | 0.91 | PDE4B (0.41) | SMN1; SMN2PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL2331253 | 0.89 | PDE4B (0.44) | PDE4BPDE4APDE4CPDE4DALDH1A1 | |
| SCHEMBL2321160 | 0.85 | PDE4B (0.46) | SMN1; SMN2PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL2331563 | 0.84 | PKM (0.46) | PDE4BPDE4APDE4CPDE4DPKM | |
| SCHEMBL2321396 | 0.84 | MAPK1 (0.45) | SMN1; SMN2PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL2321162 | 0.82 | PDE4B (0.56) | SMN1; SMN2PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL2327035 | 0.81 | PDE4B (0.43) | PDE4BPDE4APDE4CPDE4DALDH1A1 | |
| SCHEMBL2359632 | 0.80 | PDE4B (0.48) | PDE4BPDE4APDE4CPDE4DL3MBTL1 | |
| SCHEMBL2325539 | 0.78 | PDE4B (0.53) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL2327263 | 0.78 | PDE4B (0.48) | PDE4BPDE4APDE4CPDE4DKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2356103-B1 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | TAKEDA GMBH (DE) | 2015-08-26 | — | — | EP | claimed |
| US-8609848-B2 | Pyrazolone-derivatives and their use as PDE-4 inhibitors | TAKEDA GMBH (DE) | 2013-12-17 | — | — | US | claimed |
| US-20110218201-A1 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PDE-4 INHIBITORS | NYCOMED GMBH (DE) | 2011-09-08 | — | — | US | claimed |
| EP-2356103-A1 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PD4 INHIBITORS | Nycomed GmbH (DE) | 2011-08-17 | — | — | EP | claimed |
| WO-2010055083-A1 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PD4 INHIBITORS | NYCOMED GMBH (DE) | 2010-05-20 | — | — | WO | claimed |
| US-9340522-B2 | Pyrazolone-derivatives and their use as PDE-4 inhibitors | TAKEDA GMBH (DE) | 2016-05-17 | — | — | US | disclosed |
| EP-2356103-B1 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | TAKEDA GMBH (DE) | 2015-08-26 | — | — | EP | disclosed |
| US-20140073672-A1 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PDE-4 INHIBITORS | TAKEDA GMBH (DE) | 2014-03-13 | — | — | US | disclosed |
| US-8609848-B2 | Pyrazolone-derivatives and their use as PDE-4 inhibitors | TAKEDA GMBH (DE) | 2013-12-17 | — | — | US | disclosed |
| US-20110218201-A1 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PDE-4 INHIBITORS | NYCOMED GMBH (DE) | 2011-09-08 | — | — | US | disclosed |
| EP-2356103-A1 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PD4 INHIBITORS | Nycomed GmbH (DE) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010055083-A1 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PD4 INHIBITORS | NYCOMED GMBH (DE) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218201-A1 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PDE-4 INHIBITORS | PDE4A, PDE3B, PDE3A | SMN1; SMN2 3764/4885PDE4B 4/4885PDE4A 1/4885 |
| US-20140073672-A1 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PDE-4 INHIBITORS | PDE4A, PDE3B, PDE3A | SMN1; SMN2 3764/4885PDE4B 4/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.